S&P 500   4,328.77 (+0.20%)
DOW   33,929.16 (-0.10%)
QQQ   358.07 (+0.04%)
AAPL   175.76 (+0.55%)
MSFT   316.27 (-0.23%)
META   298.06 (-0.34%)
GOOGL   130.37 (+0.09%)
AMZN   130.94 (+1.41%)
TSLA   244.04 (-0.34%)
NVDA   421.73 (+1.35%)
NIO   8.39 (-1.64%)
BABA   86.88 (-1.61%)
AMD   96.06 (-0.15%)
T   14.93 (-1.26%)
F   12.64 (+1.69%)
MU   68.71 (-0.25%)
CGC   0.94 (+12.41%)
GE   111.75 (+0.45%)
DIS   80.76 (-0.60%)
AMC   8.16 (+7.09%)
PFE   32.65 (-0.12%)
PYPL   58.41 (+0.92%)
NFLX   383.35 (+0.93%)
S&P 500   4,328.77 (+0.20%)
DOW   33,929.16 (-0.10%)
QQQ   358.07 (+0.04%)
AAPL   175.76 (+0.55%)
MSFT   316.27 (-0.23%)
META   298.06 (-0.34%)
GOOGL   130.37 (+0.09%)
AMZN   130.94 (+1.41%)
TSLA   244.04 (-0.34%)
NVDA   421.73 (+1.35%)
NIO   8.39 (-1.64%)
BABA   86.88 (-1.61%)
AMD   96.06 (-0.15%)
T   14.93 (-1.26%)
F   12.64 (+1.69%)
MU   68.71 (-0.25%)
CGC   0.94 (+12.41%)
GE   111.75 (+0.45%)
DIS   80.76 (-0.60%)
AMC   8.16 (+7.09%)
PFE   32.65 (-0.12%)
PYPL   58.41 (+0.92%)
NFLX   383.35 (+0.93%)
S&P 500   4,328.77 (+0.20%)
DOW   33,929.16 (-0.10%)
QQQ   358.07 (+0.04%)
AAPL   175.76 (+0.55%)
MSFT   316.27 (-0.23%)
META   298.06 (-0.34%)
GOOGL   130.37 (+0.09%)
AMZN   130.94 (+1.41%)
TSLA   244.04 (-0.34%)
NVDA   421.73 (+1.35%)
NIO   8.39 (-1.64%)
BABA   86.88 (-1.61%)
AMD   96.06 (-0.15%)
T   14.93 (-1.26%)
F   12.64 (+1.69%)
MU   68.71 (-0.25%)
CGC   0.94 (+12.41%)
GE   111.75 (+0.45%)
DIS   80.76 (-0.60%)
AMC   8.16 (+7.09%)
PFE   32.65 (-0.12%)
PYPL   58.41 (+0.92%)
NFLX   383.35 (+0.93%)
S&P 500   4,328.77 (+0.20%)
DOW   33,929.16 (-0.10%)
QQQ   358.07 (+0.04%)
AAPL   175.76 (+0.55%)
MSFT   316.27 (-0.23%)
META   298.06 (-0.34%)
GOOGL   130.37 (+0.09%)
AMZN   130.94 (+1.41%)
TSLA   244.04 (-0.34%)
NVDA   421.73 (+1.35%)
NIO   8.39 (-1.64%)
BABA   86.88 (-1.61%)
AMD   96.06 (-0.15%)
T   14.93 (-1.26%)
F   12.64 (+1.69%)
MU   68.71 (-0.25%)
CGC   0.94 (+12.41%)
GE   111.75 (+0.45%)
DIS   80.76 (-0.60%)
AMC   8.16 (+7.09%)
PFE   32.65 (-0.12%)
PYPL   58.41 (+0.92%)
NFLX   383.35 (+0.93%)
NASDAQ:SCYX

SCYNEXIS (SCYX) Stock Forecast, Price & News

Notice: Trading of SCYNEXIS halted at 08:25 AM EST due to "News pending".
$2.26
-1.05 (-31.72%)
(As of 11:10 AM ET)
Compare
Today's Range
$1.73
▼
$2.33
50-Day Range
$2.67
▼
$3.65
52-Week Range
$1.15
▼
$3.87
Volume
2.57 million shs
Average Volume
834,588 shs
Market Capitalization
$84.03 million
P/E Ratio
2.69
Dividend Yield
N/A
Price Target
$11.40
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

SCYNEXIS MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
516.2% Upside
$11.40 Price Target
Short Interest
Healthy
3.58% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.51mentions of SCYNEXIS in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-89.19%
From $2.22 to $0.24 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

371st out of 963 stocks

Pharmaceutical Preparations Industry

165th out of 459 stocks

See Top Rated MarketRank™ Stocks Here

SCYX stock logo

About SCYNEXIS (NASDAQ:SCYX) Stock

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of various fungal infections, including invasive candidiasis, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

SCYX Price History

SCYX Stock News Headlines

September 25, 2023 | reuters.com
Scynexis to recall antifungal from market, pause studies
September 25, 2023 | marketwatch.com
Scynexis Shares Slide Premarket on Brexafemme Recall, Study Hold >SCYX
September 25, 2023 | Edge On The Street (Ad)
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
September 21, 2023 | americanbankingnews.com
SCYNEXIS, Inc. (NASDAQ:SCYX) Receives $11.40 Consensus PT from Analysts
September 12, 2023 | finance.yahoo.com
SCYNEXIS, Inc.'s (NASDAQ:SCYX) Stock Is Going Strong: Have Financials A Role To Play?
September 4, 2023 | finance.yahoo.com
SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why
August 28, 2023 | finance.yahoo.com
SCYNEXIS to Participate in September Investor Conferences
August 16, 2023 | markets.businessinsider.com
SCYNEXIS (SCYX) Receives a Buy from Maxim Group
September 25, 2023 | Edge On The Street (Ad)
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
August 16, 2023 | finance.yahoo.com
Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues
August 15, 2023 | finanznachrichten.de
Scynexis: SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 15, 2023 | msn.com
Cantor Fitzgerald Reiterates Scynexis (SCYX) Overweight Recommendation
August 14, 2023 | seekingalpha.com
SCYNEXIS GAAP EPS of $2.46 beats by $1.01, revenue of $131.5M beats by $36.1M
August 14, 2023 | chron.com
Scynexis: Q2 Earnings Snapshot
August 14, 2023 | finance.yahoo.com
SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 10, 2023 | msn.com
Amylyx Pharmaceuticals, Inc. (AMLX) Surpasses Q2 Earnings and Revenue Estimates
July 24, 2023 | benzinga.com
AUROBAC THERAPEUTICS welcomes two new independent members to its Board: Manos Perros, as Chairman, and Marco Taglietti
July 20, 2023 | finanznachrichten.de
Scynexis: SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China
July 20, 2023 | finance.yahoo.com
SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China
June 22, 2023 | finance.yahoo.com
SCYX Sep 2023 2.500 put
June 22, 2023 | finance.yahoo.com
SCYX Jul 2023 5.000 call
June 21, 2023 | finanznachrichten.de
Scynexis: SCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement with GSK
June 21, 2023 | finance.yahoo.com
SCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement with GSK
June 20, 2023 | barrons.com
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating SCYNEXIS, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
June 15, 2023 | finance.yahoo.com
SCYNEXIS to Participate in the Maxim Group Virtual Healthcare Conference
May 19, 2023 | seekingalpha.com
Scynexis: A Disappointing Q1 Earnings And Cooling GSK Catalyst - We Maintain Neutral Rating
May 19, 2023 | benzinga.com
WBB Research Institute Webcast Highlighted the Need For a Global Response to Candida auris and Other Deadly Antimicrobial Resistant Pathogens
See More Headlines
Receive SCYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SCYNEXIS and its competitors with MarketBeat's FREE daily newsletter.

SCYX Company Calendar

Last Earnings
8/14/2023
Today
9/25/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SCYX
CUSIP
N/A
CIK
1178253
Web
www.scynexis.com
Phone
(201) 884-5485
Fax
201-884-5490
Employees
36
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.40
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+244.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$0.84
Trailing P/E Ratio
3.94
Forward P/E Ratio
1.49
P/E Growth
N/A
Net Income
$-62,810,000.00
Net Margins
32.71%
Pretax Margin
32.71%
Return on Equity
317.92%
Return on Assets
62.50%

Debt

Debt-to-Equity Ratio
0.12
Current Ratio
9.01
Quick Ratio
8.37

Sales & Book Value

Annual Sales
$5.09 million
Price / Sales
24.18
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.10 per share
Price / Book
33.10

Miscellaneous

Outstanding Shares
37,180,000
Free Float
35,540,000
Market Cap
$123.07 million
Optionable
Optionable
Beta
2.14
Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. David Gonzalez Angulo M.D. (Age 58)
    CEO, Pres & Director
    Comp: $631.69k
  • Mr. Scott Sukenick J.D. (Age 45)
    Chief Legal Officer & Corp. Sec.
    Comp: $542.05k
  • Mr. Ivor Macleod CPA (Age 62)
    M.B.A., Chief Financial Officer
  • Debbie Etchison
    Exec. Director of Communications
  • Ms. Daniella Gigante
    VP of HR & Information Technology

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













SCYX Stock - Frequently Asked Questions

Should I buy or sell SCYNEXIS stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SCYX shares.
View SCYX analyst ratings or view top-rated stocks.

What is SCYNEXIS's stock price forecast for 2023?

4 brokerages have issued 12 month price objectives for SCYNEXIS's shares. Their SCYX share price forecasts range from $8.00 to $15.00. On average, they expect the company's share price to reach $11.40 in the next year. This suggests a possible upside of 244.4% from the stock's current price.
View analysts price targets for SCYX or view top-rated stocks among Wall Street analysts.

How have SCYX shares performed in 2023?

SCYNEXIS's stock was trading at $1.56 on January 1st, 2023. Since then, SCYX shares have increased by 112.2% and is now trading at $3.31.
View the best growth stocks for 2023 here.

When is SCYNEXIS's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our SCYX earnings forecast.

How were SCYNEXIS's earnings last quarter?

SCYNEXIS, Inc. (NASDAQ:SCYX) posted its quarterly earnings results on Monday, August, 14th. The company reported $2.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $1.43. The firm had revenue of $131.45 million for the quarter, compared to the consensus estimate of $91.50 million. SCYNEXIS had a trailing twelve-month return on equity of 317.92% and a net margin of 32.71%.

When did SCYNEXIS's stock split?

Shares of SCYNEXIS reverse split before market open on Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 16th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of SCYNEXIS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SCYNEXIS investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Sorrento Therapeutics (SRNE), Gran Tierra Energy (GTE), KushCo (KSHB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Outlook Therapeutics (OTLK), Cogent Biosciences (UMRX) and Aeterna Zentaris (AEZS).

What is SCYNEXIS's stock symbol?

SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."

Who are SCYNEXIS's major shareholders?

SCYNEXIS's stock is owned by many different retail and institutional investors. Top institutional investors include Stonepine Capital Management LLC (8.07%), Stonepine Capital Management LLC (8.07%), BlackRock Inc. (1.18%), D.A. Davidson & CO. (0.99%), Geode Capital Management LLC (0.85%) and Walleye Capital LLC (0.65%). Insiders that own company stock include Brian Philippe Tinmouth, Eric Francois, Marco Taglietti, Perceptive Advisors Llc and Scott Sukenick.
View institutional ownership trends.

How do I buy shares of SCYNEXIS?

Shares of SCYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SCYNEXIS's stock price today?

One share of SCYX stock can currently be purchased for approximately $3.31.

How much money does SCYNEXIS make?

SCYNEXIS (NASDAQ:SCYX) has a market capitalization of $123.07 million and generates $5.09 million in revenue each year. The company earns $-62,810,000.00 in net income (profit) each year or $0.84 on an earnings per share basis.

How can I contact SCYNEXIS?

SCYNEXIS's mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The official website for the company is www.scynexis.com. The company can be reached via phone at (201) 884-5485, via email at ikoffler@lifesciadvisors.com, or via fax at 201-884-5490.

This page (NASDAQ:SCYX) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -